Two Distinct Diseases, One Dupixent: Inhibition of two of the Key Cytokines in COPD and Asthma

This engaging event, hosted on February 4, 2025, at Ruth’s Chris Steak House in Honolulu explores the cutting-edge role of Dupixent (dupilumab) in treating Chronic Obstructive Pulmonary Disease (COPD) and asthma.

Led by Dr. Cedric Rutland, MD, a renowned pulmonologist, the discussion will highlight how Dupixent’s dual inhibition of key cytokines addresses the underlying mechanisms of these challenging conditions. Attendees will gain a deeper understanding of its approved indications for COPD with an eosinophilic phenotype and as an add-on treatment for asthma in both adult and pediatric populations.

The session will delve into Dupixent’s safety and efficacy, practical considerations for patient selection, and the latest clinical data. It will also cover important precautions, contraindications, and its use in special populations, such as pregnant or breastfeeding patients.

This event is an excellent opportunity for healthcare providers to enhance their knowledge of innovative respiratory therapies while enjoying a collegial atmosphere. Dinner will be provided, and attendees are encouraged to RSVP early to secure their spot. Please note that CME credits will not be offered.